NCT Number: NCT00073138
A Study of ABT-751 in Patients With Colorectal Cancer
The purpose of the study is to determine if ABT-751 will decrease tumors, and determine how long the tumor shrinkage can be maintained in patients with colorectal cancer. Patients will receive ABT-751 by mouth daily for 21 days. Patients will be off drug for 7 days before starting the next cycle of drug.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 2
Primary location
University of Southern California, Los Angeles, California, United States
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Colorectal cancer.
- Recurrent tumor following treatment with irinotecan and/or oxaliplatin.
- Able to tolerate normal activities of daily living.
- Adequate bone marrow, kidney, and liver function.
Exclusion criteria
- Pregnant or breast feeding.
- Anti-tumor therapy within 4 weeks of the start of ABT-751 administration.
- Prior radiation therapy.
- CNS metastasis.
Treatment and study plan
Primary outcomes
-
Objective Response Rate in subjects with Recurrent Colorectal Cancer
Time frame: 1 year
Secondary outcomes
-
Time to Tumor Progression (TTP)
Time frame: 1 year
-
Survival
Time frame: 2 years
-
Toxicities associated with treatment administration
Time frame: 1 year
Sponsors and collaborators
Lead sponsor
Abbott
Industry
Registry information
Official study title
A Phase 2 Study of ABT-751 in Subjects With Refractory Colorectal Carcinoma
Important dates
- Study start
- 2003
- Study completion
- 2005
- First posted
- Nov 18, 2003
- Registry last updated
- Nov 29, 2007
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Telerehabilitation in Cancer Patients: Optimization of Prehabilitation and Rehabilitation Following Colorectal Resection
NCT06593678
Colonic Diseases, Colorectal Cancer
Zaragoza, Spain
View Trial DetailsCetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
NCT00265850
Colonic Diseases, Colonic Neoplasms
Mobile, Alabama, United States
View Trial DetailsPsychological Evaluation According Colonic Colonization by Escherichia Coli of Patients After Colorectal Surgery
NCT02970513
Bacterial Infections, Bacterial Infections and Mycoses
Clermont-Ferrand, France
View Trial DetailsTumor-Derived FGF19
NCT06068257
Breast Cancer, Breast Diseases
Orlando, Florida, United States
View Trial Details